Reports
Reports
Sale
The cell and gene therapy market size was valued at USD 17.4 billion in 2023, driven by the increasing prevalence of chronic disorders like cancer across the globe. The market size is anticipated to grow at a CAGR of 23.17% during the forecast period of 2024-2032 to achieve a value of USD 113.53 billion by 2032.
Cell and Gene Therapy Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell and Gene Therapy Market Overview
3.1 Global Cell and Gene Therapy Market Historical Value (2017-2023)
3.2 Global Cell and Gene Therapy Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Cell and Gene Therapy Market Landscape*
5.1 Global Cell and Gene Therapy: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Cell and Gene Therapy: Product Landscape
5.2.1 Analysis by Therapy Type
5.2.2 Analysis by Indication
6 Global Cell and Gene Therapy Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Cell and Gene Therapy Market Segmentation (2017-2032)
7.1 Global Cell and Gene Therapy Market (2017-2032) by Therapy Type
7.1.1 Market Overview
7.1.2 Cell Therapy Types
7.1.2.1 Autologous Cell Therapy
7.1.2.2 Allogenic Cell Therapy
7.1.3 Gene Therapy Types
7.1.3.1 Somatic Gene Therapy
7.1.3.2 Germline Gene Therapy
7.2 Global Cell and Gene Therapy Market (2017-2032) by Type
7.2.1 Market Overview
7.2.2 Cell Type
7.2.2.1 Stem Cell
7.2.2.2 Non-Stem Cell
7.2.3 Gene Type
7.2.3.1 Antigen
7.2.3.2 Cytokine
7.2.3.3 Tumor Suppressor
7.2.3.4 Growth Factors
7.2.3.5 Receptors
7.2.3.6 Others
7.3 Global Cell and Gene Therapy Market (2017-2032) by Delivery Mode
7.3.1 Market Overview
7.3.2 In Vivo
7.3.3 Ex Vivo
7.4 Global Cell and Gene Therapy Market (2017-2032) by Vector Type
7.4.1 Market Overview
7.4.2 Viral Vector
7.4.3 Non-viral Techniques
7.5 Global Cell and Gene Therapy Market (2017-2032) by Therapeutic Area
7.5.1 Market Overview
7.5.2 Oncology
7.5.3 Cardiovascular Diseases
7.5.4 Neurological Disorders
7.5.5 Genetic Disorders
7.5.6 Infectious Diseases
7.5.7 Hematological Disorders
7.5.8 Musculoskeletal Disorders
7.5.9 Others
7.6 Global Cell and Gene Therapy Market (2017-2032) by End User
7.6.1 Market Overview
7.6.2 Hospitals
7.6.3 Cancer Care Centers
7.6.4 Academic and Research Institutes
7.6.5 Others
7.7 Global Cell and Gene Therapy Market (2017-2032) by Region
7.7.1 Market Overview
7.7.2 North America
7.7.3 Europe
7.7.4 Asia Pacific
7.7.5 Latin America
7.7.6 Middle East and Africa
8 North America Global Cell and Gene Therapy Market (2017-2032)
8.1 North America Cell and Gene Therapy Market (2017-2032) by Therapy Type
8.1.1 Market Overview
8.1.2 Cell Therapy Types
8.1.2.1 Autologous Cell Therapy
8.1.2.2 Allogenic Cell Therapy
8.1.3 Gene Therapy Types
8.1.3.1 Somatic Gene Therapy
8.1.3.2 Germline Gene Therapy
8.2 North America Cell and Gene Therapy Market (2017-2032) by Type
8.2.1 Market Overview
8.2.2 Cell Type
8.2.2.1 Stem Cell
8.2.2.2 Non-Stem Cell
8.2.3 Gene Type
8.2.3.1 Antigen
8.2.3.2 Cytokine
8.2.3.3 Tumor Suppressor
8.2.3.4 Growth Factors
8.2.3.5 Receptors
8.2.3.6 Others
8.3 North America Cell and Gene Therapy Market (2017-2032) by Delivery Mode
8.3.1 Market Overview
8.3.2 In Vivo
8.3.3 Ex Vivo
8.4 North America Cell and Gene Therapy Market (2017-2032) by Vector Type
8.4.1 Market Overview
8.4.2 Viral Vector
8.4.3 Non-viral Techniques
8.5 North America Cell and Gene Therapy Market (2017-2032) by Indication
8.5.1 Market Overview
8.5.2 Oncology
8.5.3 Cardiovascular Diseases
8.5.4 Neurological Disorders
8.5.5 Genetic Disorders
8.5.6 Infectious Diseases
8.5.7 Hematological Disorders
8.5.8 Musculoskeletal Disorders
8.5.9 Others
8.6 North America Cell and Gene Therapy Market (2017-2032) by End User
8.6.1 Market Overview
8.6.2 Hospitals
8.6.3 Cancer Care Centers
8.6.4 Academic and Research Institutes
8.6.5 Others
8.7 North America Global Cell and Gene Therapy Market (2017-2032) by Country
8.7.1 United States of America
8.7.2 Canada
9 Europe Global Cell and Gene Therapy Market (2017-2032)
9.1 Europe Cell and Gene Therapy Market (2017-2032) by Therapy Type
9.1.1 Market Overview
9.1.2 Cell Therapy Types
9.1.2.1 Autologous Cell Therapy
9.1.2.2 Allogenic Cell Therapy
9.1.3 Gene Therapy Types
9.1.3.1 Somatic Gene Therapy
9.1.3.2 Germline Gene Therapy
9.2 Europe Cell and Gene Therapy Market (2017-2032) by Type
9.2.1 Market Overview
9.2.2 Cell Type
9.2.2.1 Stem Cell
9.2.2.2 Non-Stem Cell
9.2.3 Gene Type
9.2.3.1 Antigen
9.2.3.2 Cytokine
9.2.3.3 Tumor Suppressor
9.2.3.4 Growth Factors
9.2.3.5 Receptors
9.2.3.6 Others
9.3 Europe Cell and Gene Therapy Market (2017-2032) by Delivery Mode
9.3.1 Market Overview
9.3.2 In Vivo
9.3.3 Ex Vivo
9.4 Europe Cell and Gene Therapy Market (2017-2032) by Vector Type
9.4.1 Market Overview
9.4.2 Viral Vector
9.4.3 Non-viral Techniques
9.5 Europe Cell and Gene Therapy Market (2017-2032) by Indication
9.5.1 Market Overview
9.5.2 Oncology
9.5.3 Cardiovascular Diseases
9.5.4 Neurological Disorders
9.5.5 Genetic Disorders
9.5.6 Infectious Diseases
9.5.7 Hematological Disorders
9.5.8 Musculoskeletal Disorders
9.5.9 Others
9.6 Europe Cell and Gene Therapy Market (2017-2032) by End User
9.6.1 Hospitals
9.6.2 Cancer Care Centers
9.6.3 Academic and Research Institutes
9.6.4 Others
9.7 Europe Global Cell and Gene Therapy Market (2017-2032) by Country
9.7.1 United Kingdom
9.7.2 Germany
9.7.3 France
9.7.4 Italy
9.7.5 Others
10 Asia Pacific Global Cell and Gene Therapy Market (2017-2032)
10.1 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Therapy Type
10.1.1 Market Overview
10.1.2 Cell Therapy Types
10.1.2.1 Autologous Cell Therapy
10.1.2.2 Allogenic Cell Therapy
10.1.3 Gene Therapy Types
10.1.3.1 Somatic Gene Therapy
10.1.3.2 Germline Gene Therapy
10.2 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Type
10.2.1 Market Overview
10.2.2 Cell Type
10.2.2.1 Stem Cell
10.2.2.2 Non-Stem Cell
10.2.3 Gene Type
10.2.3.1 Antigen
10.2.3.2 Cytokine
10.2.3.3 Tumor Suppressor
10.2.3.4 Growth Factors
10.2.3.5 Receptors
10.2.3.6 Others
10.3 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Delivery Mode
10.3.1 Market Overview
10.3.2 In Vivo
10.3.3 Ex Vivo
10.4 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Vector Type
10.4.1 Market Overview
10.4.2 Viral Vector
10.4.3 Non-viral Techniques
10.5 Asia Pacific Cell and Gene Therapy Market (2017-2032) by Indication
10.5.1 Market Overview
10.5.2 Oncology
10.5.3 Cardiovascular Diseases
10.5.4 Neurological Disorders
10.5.5 Genetic Disorders
10.5.6 Infectious Diseases
10.5.7 Hematological Disorders
10.5.8 Musculoskeletal Disorders
10.5.9 Others
10.6 Asia Pacific Cell and Gene Therapy Market (2017-2032) by End User
10.6.1 Hospitals
10.6.2 Cancer Care Centers
10.6.3 Academic and Research Institutes
10.6.4 Others
10.7 Asia Pacific Global Cell and Gene Therapy Market (2017-2032) by Country
10.7.1 China
10.7.2 Japan
10.7.3 India
10.7.4 ASEAN
10.7.5 Australia
10.7.6 Others
11 Latin America Global Cell and Gene Therapy Market (2017-2032)
11.1 Latin America Cell and Gene Therapy Market (2017-2032) by Therapy Type
11.1.1 Market Overview
11.1.2 Cell Therapy Types
11.1.2.1 Autologous Cell Therapy
11.1.2.2 Allogenic Cell Therapy
11.1.3 Gene Therapy Types
11.1.3.1 Somatic Gene Therapy
11.1.3.2 Germline Gene Therapy
11.2 Latin America Cell and Gene Therapy Market (2017-2032) by Type
11.2.1 Market Overview
11.2.2 Cell Type
11.2.2.1 Stem Cell
11.2.2.2 Non-Stem Cell
11.2.3 Gene Type
11.2.3.1 Antigen
11.2.3.2 Cytokine
11.2.3.3 Tumor Suppressor
11.2.3.4 Growth Factors
11.2.3.5 Receptors
11.2.3.6 Others
11.3 Latin America Cell and Gene Therapy Market (2017-2032) by Delivery Mode
11.3.1 Market Overview
11.3.2 In Vivo
11.3.3 Ex Vivo
11.4 Latin America Cell and Gene Therapy Market (2017-2032) by Vector Type
11.4.1 Market Overview
11.4.2 Viral Vector
11.4.3 Non-viral Techniques
11.5 Latin America Cell and Gene Therapy Market (2017-2032) by Indication
11.5.1 Market Overview
11.5.2 Oncology
11.5.3 Cardiovascular Diseases
11.5.4 Neurological Disorders
11.5.5 Genetic Disorders
11.5.6 Infectious Diseases
11.5.7 Hematological Disorders
11.5.8 Musculoskeletal Disorders
11.5.9 Others
11.6 Latin America Cell and Gene Therapy Market (2017-2032) by End User
11.6.1 Hospitals
11.6.2 Cancer Care Centers
11.6.3 Academic and Research Institutes
11.6.4 Others
11.7 Latin America Global Cell and Gene Therapy Market (2017-2032) by Country
11.7.1 Brazil
11.7.2 Argentina
11.7.3 Mexico
11.7.4 Others
12 Middle East and Africa Global Cell and Gene Therapy Market (2017-2032)
12.1 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Therapy Type
12.1.1 Market Overview
12.1.2 Cell Therapy Types
12.1.2.1 Autologous Cell Therapy
12.1.2.2 Allogenic Cell Therapy
12.1.3 Gene Therapy Types
12.1.3.1 Somatic Gene Therapy
12.1.3.2 Germline Gene Therapy
12.2 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Type
12.2.1 Market Overview
12.2.2 Cell Type
12.2.2.1 Stem Cell
12.2.2.2 Non-Stem Cell
12.2.3 Gene Type
12.2.3.1 Antigen
12.2.3.2 Cytokine
12.2.3.3 Tumor Suppressor
12.2.3.4 Growth Factors
12.2.3.5 Receptors
12.2.3.6 Others
12.3 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Delivery Mode
12.3.1 Market Overview
12.3.2 In Vivo
12.3.3 Ex Vivo
12.4 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Vector Type
12.4.1 Market Overview
12.4.2 Viral Vector
12.4.3 Non-viral Techniques
12.5 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by Indication
12.5.1 Market Overview
12.5.2 Oncology
12.5.3 Cardiovascular Diseases
12.5.4 Neurological Disorders
12.5.5 Genetic Disorders
12.5.6 Infectious Diseases
12.5.7 Hematological Disorders
12.5.8 Musculoskeletal Disorders
12.5.9 Others
12.6 Middle East and Africa Cell and Gene Therapy Market (2017-2032) by End User
12.6.1 Hospitals
12.6.2 Cancer Care Centers
12.6.3 Academic and Research Institutes
12.6.4 Others
12.7 Middle East and Africa Global Cell and Gene Therapy Market (2017-2032) by Country
12.7.1 Saudi Arabia
12.7.2 United Arab Emirates
12.7.3 Nigeria
12.7.4 South Africa
12.7.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Clinical Trial Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Grant Analysis
15.1 Analysis by Year
15.2 Analysis by Amount Awarded
15.3 Analysis by Issuing Authority
15.4 Analysis by Grant Product
15.5 Analysis by Funding Institute
15.6 Analysis by Departments
15.7 Analysis by Recipient Organization
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Strategic Initiatives
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Market Share Analysis, By Region (Top 5 Companies)
18.1.1 Market Share Analysis: Global
18.1.2 Market Share Analysis: North America
18.1.3 Market Share Analysis: Europe
18.1.4 Market Share Analysis: Asia Pacific
18.1.5 Market Share Analysis: Others
18.2 Amgen Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Company News and Developments
18.2.5 Certifications
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Company News and Developments
18.3.5 Certifications
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Company News and Developments
18.4.5 Certifications
18.5 Bluebird Bio, Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Company News and Developments
18.5.5 Certifications
18.6 Castle Creek Pharmaceutical Holdings
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Company News and Developments
18.6.5 Certifications
18.7 Bristol-Myers Squibb
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Company News and Developments
18.7.5 Certifications
18.8 Kite Pharma, Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Company News and Developments
18.8.5 Certifications
18.9 Vericel Corporation Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Company News and Developments
18.9.5 Certifications
18.10 Kolon TissueGene Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Company News and Developments
18.10.5 Certifications
18.11 Vertex Pharmaceuticals, Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Company News and Developments
18.11.5 Certifications
18.12 Spark Therapeutics, Inc.
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Company News and Developments
18.12.5 Certifications
18.13 CORESTEM Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Company News and Developments
18.13.5 Certifications
18.14 Biogen Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Company News and Developments
18.14.5 Certifications
18.15 Dendreon Pharmaceuticals LLC.
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Company News and Developments
18.15.5 Certifications
18.16 JCR Pharmaceuticals Co. Ltd.
18.16.1 Financial Analysis
18.16.2 Product Portfolio
18.16.3 Demographic Reach and Achievements
18.16.4 Company News and Developments
18.16.5 Certifications
19 Global Cell and Gene Therapy Market – Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.